Oramed Pharmaceuticals (ORMP) Competitors $2.45 -0.06 (-2.47%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. FDMT, YMAB, EOLS, KMDA, AURA, KRRO, DSGN, DRUG, ANNX, and LXEOShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), Kamada (KMDA), Aura Biosciences (AURA), Korro Bio (KRRO), Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), Annexon (ANNX), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors 4D Molecular Therapeutics Y-mAbs Therapeutics Evolus Kamada Aura Biosciences Korro Bio Design Therapeutics Bright Minds Biosciences Annexon Lexeo Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Do insiders & institutionals hold more shares of ORMP or FDMT? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is ORMP or FDMT more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Oramed Pharmaceuticals' return on equity of -19.37% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -19.37% -18.28% 4D Molecular Therapeutics -594,375.81%-40.15%-36.43% Which has stronger earnings and valuation, ORMP or FDMT? Oramed Pharmaceuticals has higher revenue and earnings than 4D Molecular Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M74.66-$19.06M-$0.35-6.974D Molecular Therapeutics$40K9,982.13-$160.87M-$3.53-2.42 Do analysts prefer ORMP or FDMT? 4D Molecular Therapeutics has a consensus target price of $30.40, suggesting a potential upside of 255.56%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.004D Molecular Therapeutics 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has more volatility & risk, ORMP or FDMT? Oramed Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500. Does the media prefer ORMP or FDMT? In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 2 mentions for Oramed Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 1.06 beat Oramed Pharmaceuticals' score of 0.97 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summary4D Molecular Therapeutics beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.04M$10.69B$6.11B$10.54BDividend YieldN/A1.84%5.66%4.70%P/E Ratio-6.9722.1186.8126.71Price / Sales74.6634.38538.97202.98Price / CashN/A25.6126.3031.09Price / Book0.683.4612.676.57Net Income-$19.06M$210.63M$3.30B$276.78M7 Day Performance-9.63%1.82%3.55%1.96%1 Month Performance9.42%1.56%6.79%9.11%1 Year Performance3.83%-7.70%72.30%31.60% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.5062 of 5 stars$2.45-2.5%N/A+3.8%$100.04M$1.34M-6.9710News CoverageShort Interest ↓FDMT4D Molecular Therapeutics2.5331 of 5 stars$8.35-0.5%$30.40+264.1%-14.2%$391.83M$40K-2.37120YMABY-mAbs Therapeutics1.7522 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150EOLSEvolus4.13 of 5 stars$6.14+2.5%$21.25+246.1%-60.2%$387.47M$266.27M-6.27170Positive NewsKMDAKamada4.5473 of 5 stars$6.87+3.0%$13.00+89.2%+31.2%$383.56M$169.52M20.21360Positive NewsAnalyst RevisionAURAAura Biosciences1.8951 of 5 stars$6.17+0.2%$22.00+256.6%-30.6%$382.66MN/A-3.1550KRROKorro Bio1.5397 of 5 stars$42.80+5.3%$86.83+102.9%+37.6%$381.83M$2.27M-4.3970News CoverageDSGNDesign Therapeutics0.0474 of 5 stars$6.85+4.3%N/A+22.2%$374.15MN/A-6.1240DRUGBright Minds Biosciences2.9312 of 5 stars$57.45+9.0%$81.00+41.0%+4,491.4%$371.36MN/A-61.77N/APositive NewsAnalyst DowngradeANNXAnnexon3.0323 of 5 stars$3.12-7.4%$12.50+300.6%-49.3%$370.32MN/A-2.4260Positive NewsGap UpHigh Trading VolumeLXEOLexeo Therapeutics2.1622 of 5 stars$6.66-1.6%$15.33+130.2%-23.6%$365.59M$650K-2.0458Positive News Related Companies and Tools Related Companies 4D Molecular Therapeutics Competitors Y-mAbs Therapeutics Competitors Evolus Competitors Kamada Competitors Aura Biosciences Competitors Korro Bio Competitors Design Therapeutics Competitors Bright Minds Biosciences Competitors Annexon Competitors Lexeo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
